Monopar Therapeutics Inc (MNPR) - Net Assets
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has net assets worth $135.39 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($137.98 Million) and total liabilities ($2.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Monopar Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $135.39 Million |
| % of Total Assets | 98.12% |
| Annual Growth Rate | 47.88% |
| 5-Year Change | 627.67% |
| 10-Year Change | 4768.41% |
| Growth Volatility | 266.59 |
Monopar Therapeutics Inc - Net Assets Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Check MNPR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual net assets of Monopar Therapeutics Inc from 2015 to 2025. For live valuation and market cap data, see MNPR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $137.83 Million | +150.43% |
| 2024-12-31 | $55.04 Million | +884.95% |
| 2023-12-31 | $5.59 Million | -44.62% |
| 2022-12-31 | $10.09 Million | -46.73% |
| 2021-12-31 | $18.94 Million | +20.71% |
| 2020-12-31 | $15.69 Million | +24.26% |
| 2019-12-31 | $12.63 Million | +82.53% |
| 2018-12-31 | $6.92 Million | -28.08% |
| 2017-12-31 | $9.62 Million | +239.78% |
| 2016-12-31 | $2.83 Million | +2.79% |
| 2015-12-31 | $2.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Monopar Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8882221900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.69K | 0.00% |
| Other Comprehensive Income | $131.39K | 0.10% |
| Other Components | $227.20 Million | 164.84% |
| Total Equity | $137.83 Million | 100.00% |
Monopar Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Monopar Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Jinyi Media Corp
SHE:002905
|
$395.93 Million |
|
Hunan Huasheng Co Ltd
SHG:600156
|
$396.00 Million |
|
Guangdong Qunxing Toys Joint-Stock Co Ltd
SHE:002575
|
$396.04 Million |
|
Somalogic Inc
NASDAQ:SLGC
|
$396.23 Million |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
$395.83 Million |
|
Quadient SA
PA:QDT
|
$395.81 Million |
|
Hyundai Green Food Co. Ltd.
KO:453340
|
$395.75 Million |
|
TCI Co Ltd
TWO:8436
|
$395.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Monopar Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 55,036,771 to 137,827,553, a change of 82,790,782 (150.4%).
- Net loss of 13,716,894 reduced equity.
- Share repurchases of 34,999,957 reduced equity.
- New share issuances of 127,141,529 increased equity.
- Other comprehensive income increased equity by 95,397.
- Other factors increased equity by 4,270,707.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.72 Million | -9.95% |
| Share Repurchases | $35.00 Million | -25.39% |
| Share Issuances | $127.14 Million | +92.25% |
| Other Comprehensive Income | $95.40K | +0.07% |
| Other Changes | $4.27 Million | +3.1% |
| Total Change | $- | 150.43% |
Book Value vs Market Value Analysis
This analysis compares Monopar Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 313.64x to 5.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.34 | $105.90 | x |
| 2016-12-31 | $0.29 | $105.90 | x |
| 2017-12-31 | $0.92 | $105.90 | x |
| 2018-12-31 | $0.66 | $105.90 | x |
| 2019-12-31 | $1.19 | $105.90 | x |
| 2020-12-31 | $1.43 | $105.90 | x |
| 2021-12-31 | $1.52 | $105.90 | x |
| 2022-12-31 | $0.79 | $105.90 | x |
| 2023-12-31 | $0.39 | $105.90 | x |
| 2024-12-31 | $4.79 | $105.90 | x |
| 2025-12-31 | $18.60 | $105.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Monopar Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-9.95%) is above the historical average (-63.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -24.94% | 0.00% | 0.00x | 1.03x | $-962.42K |
| 2016 | -41.88% | 0.00% | 0.00x | 1.02x | $-1.47 Million |
| 2017 | -172.10% | 0.00% | 0.00x | 1.03x | $-17.52 Million |
| 2018 | -46.66% | 0.00% | 0.00x | 1.06x | $-3.92 Million |
| 2019 | -32.67% | 0.00% | 0.00x | 1.06x | $-5.39 Million |
| 2020 | -40.18% | -5150.79% | 0.01x | 1.07x | $-7.87 Million |
| 2021 | -47.93% | 0.00% | 0.00x | 1.08x | $-10.97 Million |
| 2022 | -104.01% | 0.00% | 0.00x | 1.31x | $-11.50 Million |
| 2023 | -150.37% | 0.00% | 0.00x | 1.31x | $-8.96 Million |
| 2024 | -28.32% | 0.00% | 0.00x | 1.10x | $-21.09 Million |
| 2025 | -9.95% | 0.00% | 0.00x | 1.02x | $-27.50 Million |
Industry Comparison
This section compares Monopar Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,729,232
- Average return on equity (ROE) among peers: -122.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Monopar Therapeutics Inc (MNPR) | $135.39 Million | -24.94% | 0.02x | $395.88 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $599.00K | -741.40% | 1.42x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $31.20 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $11.46 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-40.09 Million | 0.00% | 0.00x | $3.66 Billion |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more